Clinical Trials Browser

Phase 1/2 × INDUSTRY × Calcium Dobesilate × Clear all

NCT06988488 2026-02-02

A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma

Phase 1/2 Recruiting

Multiple Myeloma

NCT02343042 2025-12-22

STOMP

Phase 1/2 Recruiting

Multiple Myeloma, Recurrence

NCT02773030 2024-06-25

A Study to Determine Dose, Safety, Tolerability, Drug Levels, and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Participants With Multiple Myeloma

Phase 1/2 Active not recruiting

Multiple Myeloma, Recurrence

NCT02206425 2023-10-31

Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients

Phase 1/2 Completed

Multiple Myeloma, Recurrence

NCT03481556 2022-12-19

ANCHOR

Phase 1/2 Terminated

56 enrolled 22 charts

Multiple Myeloma

NCT01464034 2022-08-01

A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Phase 1/2 Terminated

Multiple Myeloma

NCT01455389 2022-03-02

TUSC2-nanoparticles and Erlotinib in Stage IV Lung Cancer

Phase 1/2 Terminated

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02862145 2016-09-27

MRX34-102

Phase 1/2 Withdrawn

Melanoma

NCT01541332 2016-03-10

Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Relapsed/Refractory Multiple Myeloma

Phase 1/2 Unknown

Multiple Myeloma

NCT00776802 2013-06-25

GCS-100LE

Phase 1/2 Withdrawn

Recurrence, Lymphoma, Large B-Cell, Diffuse